Skip to main content

Clinical value of baseline 18F-FDG PET/CT in soft tissue sarcomas



The use of 18F-FDG Positron emission tomography/Computed tomography (PET/CT) in the initial staging of many cancers is clearly established. Most soft tissue sarcoma (STS) has a high affinity for 18F-FDG, which is why 18F-FDG PET/CT has been proposed as a non-invasive method, useful in diagnosis and follow-up. The standardized uptake value values (SUV), the volume-based metabolic parameters MTV (metabolic tumor volume), and TLG (total lesion glycolysis) determine tumor viability and provide its total volume and the total activity of metabolically active tumor cells. The histological grade is the most important predictor of metastases and mortality associated with STS, and a significant relationship between the metabolic parameters of 18F-FDG PET/CT and the histological grade has been described.


A retrospective study was conducted on STS patients, who had histological grade according to the FNCLCC (Fédération Nationale des Centres de Lutte Contre Le Cancer) criteria, as well as a baseline PET/CT. SUV (SUVmax, SUVmean, and SUVpeak), MTV, and TLG were quantified. A T-student test was performed to establish the relationship between the metabolic biomarkers and the histological grade. Their usefulness as predictors of the histological grade was verified using receiver operator characteristic (ROC) curves. A survival function study was performed using the Kaplan–Meier method. To assess the prognostic utility of the metabolic biomarkers we use the Log-Rank method.


The SUV values were useful to discriminate high-grade STS. We found a significant relationship between the histological grade and the SUV values. SUVmax, SUVpeak, MTV, and TLG were predictors of overall survival (OS). There were no significant differences in the OS for the SUVmean, or in the disease-free survival (DFS) for SUVmax, SUVmean, SUVpeak, MTV, and TLG.


The SUVmax, SUVmean, and SUVpeak values correlate with the HG and are useful to discriminate high-grade from low-grade STS. Patients with high SUVmax, SUVpeak, MTV, and TLG have a significantly lower OS.


Soft tissue sarcomas (STS) are a group of rare tumors derived from mesenchymal tissues, whose cells develop in the circulatory and lymphatic systems, as well as in structural and connective tissues. Tumors that derive from peripheral nerves by convention are also classified as sarcomas, despite their embryological origin in the neural crest. Their great variety is due to the tissues in which they originate, with diverse clinical and biological behavior (Beckingsale and Shaw 2017). In Spain, the incidence rate of sarcomas is 18 to 20 cases per million in children, of which 6.5% are STS (Sarcomas en la Infancia 2020), with 2.000 total cases/year (Acciones and para que el Gobierno actúe sobre el Sarcoma (plan 20192020)). In Europe the estimated incidence is 5 new cases/100.000 inhabitants/year, corresponding to 1% of neoplasms in adults (Guerra Merino 2017). In the United States (U.S.), 13,130 new STS were diagnosed (7240 males and 5510 females) in 2020 (Key Statistics for Soft Tissue Sarcomas 2019). Both sexes are equally affected; the incidence is higher in females in the 45–49 age group, due to gynecological tumors (Beckingsale and Shaw 2017; López-Pousa et al. 2016). Liposarcoma and leiomyosarcoma are the most frequent STS (Francis et al. 1996; Stiller et al. 2013; Corey et al. 2014). Limbs are the most frequent location. However, the anatomic location varies according to the histological classification of the tumor (Bray et al. 2017; Brennan et al. 2014). In the United States, the most favorable survival rates are for dermatofibrosarcoma (92% 5-year survival), with a worse prognosis for undifferentiated chondrosarcoma (5-year survival 19%) (Corey et al. 2014). In Europe, the highest survival rate is for cutaneous STS (90%), while those of the mediastinum and heart have survival rates of less than 15% (Stiller et al. 2013). According to the National Cancer Institute (NCI), survival is determined by stage. The 5-year relative survival rates are 81% in stage 1 (localized), 58% in stage 2 (lymphatic spread), 16% in stage 3 (distant metastases), and 55% in unstaged sarcomas (National Cancer Society (NCS) 2020).

Classification and grading

Pathological diagnosis, according to morphology, immunohistochemistry, and molecular analysis, provides data for the prognosis, quality of surgical resection, and treatment response (Villalobos León 2013). STS are classified according to the criteria of the World Health Organization (WHO), embodying data of molecular cytogenetics and pathogenesis (Fletcher et al. 2013; Vilanova 2017). The histological type doesn’t provide enough prognostic information. The histological grade is the most important predictor of metastases and mortality associated with STS (Fletcher et al. 2002). Trojani et al. (1984), established the pathological criteria correlated with the advent of metastases and survival and set up a grading system based on differentiation, mitotic count, and tumor necrosis, published by the FNCLCC (Fédération Nationale des Centres de Lutte Contre Le Cancer). FNCLCC grading system assigns a score according to the histological criteria, the sum of which determines the histological grade (grade 1, 2, and 3) (Coindre et al. 2001). The Union for International Cancer Control (UICC) (Brierley et al. 2017) summarizes the grading of STS in a two-grade system (FNCLCC grades 2 and 3 are classified as high-grade, and grade 1 as a low-grade).

The role of 18F-FDG PET/CT in soft tissue sarcoma

Nuclear medicine provides metabolic information as an indirect measure of cellular function, based on the interaction of tissues with radioactive elements (Isabel and José 2020). The hybrid imaging, and mass production of 2-deoxy-2-[18F] fluoro-D-glucose (18F-FDG), improved the accuracy and diagnostic performance of molecular imaging, increasing oncology indications for Positron emission tomography/Computed tomography (PET/CT).

The 18F-FDG accumulation is mediated by the Glucose-transporter family (GLUT), located in the cell membranes, and regulates the uptake of glucose. The most important subtypes (GLUT 1 and GLUT 3) are overexpressed in tumors. Tumor cells need more glucose for proliferation than physiological cells because of the ineffective aerobic glycolysis (Warburg effect). The existence of this metabolic switch such reprogramming of cell energy metabolism must compensate for the lower efficiency of ATP production upregulating glucose transporters, which suggests that metabolic protein expression is associated with tumor aggressiveness and treatment response (Meyer et al. 2019). GLUT is also expressed in sarcomas (e.g., 50% of intrauterine leiomyosarcomas and 25% of extrauterine sarcomas by immunohistochemistry), and his positivity correlates closely with aggressive biological behavior, reflected by distant metastatic spread. In some cases, there was no detectable expression of GLUT in sarcoma, which suggests that another glucose transporter maintains glycolytic metabolism in these tumors, or that GLUT is expressed at specific stages of carcinogenesis. Some tumors have been found to contain subpopulations of cancer cells that differ in their energy-generating pathways. One subpopulation consists of glucose-dependent (‘‘Warburg-effect’’) cells that secrete lactate, whereas cells of the second subpopulation preferentially import and utilize the lactate as their main energy source, functioning symbiotically. Soft tissue sarcomas are extremely heterogeneous since they arise in a multitude of tissues of many different cell lines, so this mechanism of energy symbiosis could be characteristic of their biological behavior. Glycolytic fueling can also activate oncogenes (RAS, MYC) and mutant tumor suppressors (TP53), which can be found in some syndromes associated with sarcomas (Carvalho et al. 2011).

The 18F-FDG is transported into the cells like glucose at a much higher rate, then it is phosphorylated to FDG-6-phosphate by hexokinase or glucokinase action, and does not enter the standard metabolic pathways, and can leave the cell only slowly by the action of glucose-6-phosphatase, so it is trapped in the neoplastic cells (Miele et al. 2008). Several hexokinase subtypes have also been described. Hexokinase I and in particular hexokinase II (HK-II) have been found to be expressed in tumors. Some authors suggest that HK-II regulating glucose metabolism in cancer cells, and the phosphorylation step may be rate-limiting in the FDG uptake and also suggest that the lack of glucose-6-phosphatase activity in tumors plays a role in determining FDG retention by preventing dephosphorylation (FDG-6-P to FDG). Thus, higher levels of GLUT do not guarantee increased 18F-FDG uptake by cancer cells, and metabolic trapping appears more likely as the rate-determining step in 18F-FDG uptake and maintaining the rapid uptake of glucose via GLUT-1 (Yang et al. 2019). Studies have shown that expression of GLUT1 and HK-II in epithelial cancer cells, including breast, esophageal, and lung cancer cells, plays a pivotal role in glucose metabolism and that the expression levels of GLUT1 and HK-II are correlated with malignancy (Tsukada et al. 2012). Sarcomas, like other tumors, display abnormal metabolic activity patterns, and detailed data regarding the STS metabolome is relatively sparse. Different oncogenes and tumor suppressors implicated in metabolic pathway regulation are mutated in sarcomas, like PIK3CA, and NF1. Furthermore, hypoxic tumor microenvironments, characteristic of sarcomas, modify metabolism and correlate with worse prognosis. Sarcoma cells display elevated glucose uptake and turnover, and glycolysis may be a key feature for tumor growth, correlated with his biological features (Esperança-Martins et al. 2021).

18F-FDG PET can be used to obtain quantitative parameters according to the tissues metabolic activity. There are different methods to quantify 18F-FDG activity, and compartmental models have been developed to calculate its concentration, to create a standardized method that allows comparable measurements. The standardized uptake value (SUV) is the most widely used quantitative imaging biomarker, also known as semi-quantitative analysis (Kinahan and Fletcher 2010; Thie 2004). Most STS have a high affinity for 18F-FDG, which is why PET/CT has been proposed as a non-invasive method, useful in diagnosis and follow-up. A significant relationship between the metabolic parameters of 18F-FDG PET/CT and the histological grade in STS has been found (Rakheja and Probst 2013; Ioannidis and Lau 2003; Macpherson et al. 2018). Volume-based metabolic parameters, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG), provide the total volume and total activity of metabolically active tumor cells (Hong et al. 2014). This work aims to establish the correlation between SUV (SUVmax, SUVmean, and SUVpeak), MTV, and TLG values of the baseline 18F-FDG PET/CT and the histological grade (FNCLCC) in patients with STS. Likewise, we analyze the usefulness of SUV, and volume-based metabolic parameters of baseline 18F-FDG PET/CT, as prognostic factors in overall survival (OS) and disease-free survival (DFS).

Materials and methods

A retrospective study was conducted on patients diagnosed with STS who had histological grade according to the FNCLCC criteria, as well as a baseline 18F-FDG PET/CT (hereinafter PET/CT). The European Association of Nuclear Medicine (EANM) recommendations for the administered activity of 18F-FDG and study acquisition were followed (Boellaard et al. 2015). SUVmax, SUVmean, SUVpeak, and MTV values ​​were obtained for the main lesion. A VOI (volume of interest) was performed using the semi-automatic MVBT (maximum voxel-based thresholding) technique, with a threshold equal to 40% of SUVmax (Vanderhoek et al. 2013). For lesions with SUVmax less than 3, and those located near to physiological activity, an adaptive threshold-based spherical VOI was used, adjusted to a SUVmax threshold of 2 (Cheebsumon et al. 2011). The TLG was calculated according to the literature (Larson et al. 1999; Mucientes et al. 2018).

The quantitative variables were expressed as means and standard deviation, and the qualitative values as frequencies and percentages. The usefulness of metabolic biomarkers (SUV, MTV, and TLG values) as predictor variables of the histological grade was evaluated, using receiver operator characteristic (ROC) curves, calculating the area under the curve (AUC) with a 95% confidence interval (CI). A T-student test was performed to establish the relationship between the metabolic biomarkers measured in the baseline study and the histological grade. A survival function study was performed using the Kaplan–Meier method, calculating the OS and DFS. To assess the prognostic utility of the metabolic biomarkers, we use the Log-Rank method. The values of each variable measured in the baseline study were ordered, and two groups were created with the median value as the cut-off point. Paired OS and DFS curves were developed, looking for significant differences between them. All results were considered significant with alpha level < 0.05. The analysis was performed with SPSS v.20.0.


Eighty-three patients, 42 men, and 41 women were analyzed. The mean age at diagnosis was 50.62 years. Median blood glucose was 128 mg/dl (range 78–180 mg/dl). Seventy-six percent of the STS were high-grade (grades 2 and 3 according to the FNCLCC) (Fig. 1). Forty percent of the patients had metastases in the baseline PET/CT of which 87.88% were high-grade (Fig. 2, Table 1). The most common tumor types were adipocytic tumors (31%), smooth muscle tumors (16%), fibroblastic/myofibroblastic tumors (13%), and undifferentiated or unclassified sarcomas (13%). The most frequent tumor subtypes were liposarcomas (34%), leiomyosarcomas (14%), and undifferentiated pleomorphic sarcomas (12%). The most frequent locations were the lower limbs (45%), abdominal and retroperitoneal (30%), and the upper extremities (12%). The TLG and SUV ​​(SUVmax, SUVmean, SUVpeak) median values in the baseline PET/CT were higher in the high-grade than in the low-grade STS (Table 2).

Fig. 1

Distribution by histological grade (FNCLCC) in the baseline 18F-FDG PET/CT

Fig. 2

Distribution of baseline 18F-FDG PET/CT with metastasis according to histological grade

Table 1 Metastases and locations in high-grade and low-grade tumors in the baseline 18F-FDG PET/CT
Table 2 Median values of the metabolic biomarkers measured in the baseline 18F-FDG PET/CT according to the histological grade

The usefulness of the metabolic parameters measured in the baseline PET/CT to discriminate high-grade from low-grade soft tissue sarcomas, was established using ROC curves, setting the following values as significant cut-off points: SUVmax 3.9 [AuC 0,824 (95% CI 0.717–0.931)], SUVmean 2,5 [AuC 0.798 (95% CI 0.682–0.914)] and SUVpeak 3.73 [AuC 0.817 (95% CI 0.708–0.926)], being the SUVmax value the most accurate. The MTV and TLG parameters did not allow to define a significant cut-off point (Fig. 3). The T-student test found a statistically significant relationship between the histological grade and the metabolic parameters of the baseline PET/CT in the SUVmax [p = 0.04 (95% CI − 10.12 a − 1.93)], SUVmean [p = 0.01 (95% CI − 3.62 a − 0.42)], and SUVpeak [p = 0.006 (95% CI − 8.35 a − 1.44)] values. No statistically significant relationship was found for the MTV (p = 0.36) or TLG (p = 0.34) values.

Fig. 3

ROC curves. Metabolic biomarkers of the baseline 18F-FDG PET/CT

A survival study was performed using the Kaplan–Meier method [OS 55.2 months (95% CI of 46.5–64)], [DFS 47.9 months (95% CI 36.9–58.8)] (Fig. 4). The Log-Rank study confirmed the prognostic value of baseline PET/CT SUVmax [p = 0.037 (95% CI 12.5–69.4)], SUVpeak [p = 0.05 (95% CI 13.1–68.8)], MTV [p = 0.022 (95% CI 7.8–74.1)], and TLG [p = 0.022 (95% CI 30.9–59)] values for OS. There were no significant differences in the OS for the SUVmean (p = 0.141), or in the DFS for SUVmax (p = 0.51), SUVmean (p = 0.74), SUVpeak (p = 0.60), MTV (p = 0.91), and TLG (p = 0.19) values (Figs. 5, 6).

Fig. 4

A Overall survival and B disease-free survival

Fig. 5

Log-Rank study. OS curves according to SUVmax, SUVmean, SUVpeak, MTV and TLG values in the baseline PET/CT

Fig. 6

Log-Rank study. DFS curves according to SUVmax, SUVmean, SUVpeak, MTV and TLG values in the baseline PET/CT


The use of PET/CT in the initial staging and restaging of many cancers has been established (Rodríguez-Alfonso et al. 2014). Molecular imaging with PET/CT is certainly a powerful tool for the initial assessment of sarcomas and the detection of their recurrences (Charest et al. 2009 Dec). The 18F-FDG PET/CT is useful to differentiate malignant (SUVmax 0.6—14, mean: 5.9) from benign (SUVmax 1.2–6.2, mean: 3.5) lesions in STS patients (p < 0.001), with different uptake patterns according to the histological type (Nose et al. 2013). According to Massardo et al. (2012), the SUVmax value is related to histological grade, mitotic activity, and cellularity. Other authors have also found significant differences between the SUVmax values of high-grade and low-grade STS, regardless of the histological subtype (Bastiaannet et al. 2004). In a German study, the mean SUVmax value was 1.3 (range 0.37–1.9) for grade 1 STS, 2.7 (range 1.2–6) for grade 2, and 4.5 (range 1.4–9.1) for grade 3, with a statistically significant difference between them (p < 0.001) (Schwarzbach et al. 2000). For Benz et al. (Benz et al. 2010), a SUVmax value of 5.2 would be the optimal cut-off point (sensitivity: 74%, specificity: 91%, AbC: 0.85) to differentiate high-grade from low-grade STS. Our analysis also suggests that SUV values (SUVmax 3.9 [AuC 0.824 (95% CI 0.717–0.931)], SUVmean 2,5 [AuC 0,798 (95% CI 0.682–0.914)] and SUVpeak 3.73 [AuC 0.817 (95% CI 0.708–0.926)], can be used to distinguish between high-grade and low-grade STS, being the SUVmax value the most accurate. Likewise, we found a significant relationship between the histological grade (FNCLCC) of the STS, and the SUVmax, SUVmean, and SUVpeak values measured in the baseline PET/CT [SUVmax [p = 0.04 (95% CI − 10.12 a − 1.93)], SUVmean [p = 0.01 (95% CI − 3.62 a − 0.42)], and SUVpeak [p = 0.006 (95% CI − 8.35 a − 1.44)]. According to the Memorial Sloan-Kettering Cancer Center and the European Organization for Research and Treatment of Cancer, the incidence of metastasis increases with tumor grade, and 90% of STS patients that develop lung metastases have high-grade lesions (Chao and Goldberg 2000; Billingsley et al. 1999); 75.8% of our population had high-grade STS (grade 2 and 3 FNCLCC), and 87.88% of the patients who developed distant metastases had a high-grade STS.

Other quantification parameters that evaluate the total volume of the tumor have been developed. Larson et al. (1999), introduced in 1999 the volume-based metabolic parameters MTV and TLG, as possible metabolic biomarkers that could be relevant in clinical practice (Mucientes et al. 2018). Choi et al. (2013) concluded that the TLG has a greater accuracy to discriminate high-grade from low-grade STS (AuC 0.802) than the SUVmax (AuC 0.726) and MTV (AuC 0.681) values. These findings are not consistent with our results, since according to our analysis, the MTV and TLG parameters did not allow us to define a significant cut-off point to discriminate high-grade from low-grade STS; neither did we find a statistically significant relationship for the MTV (p-0.36) or TLG (p-0.34) values with the histological grade, which can be explained by Schwarzbach et al. (2000). He found a significant relationship between the metabolic activity of the tumor and the histological grade, regardless of size, since the SUV value increases with the histological grade, and not with the size of the lesion. This discordance could also be due to the heterogeneity of demographics, and histological characteristics of the analyzed patients.

In our results MTV was larger in low-grade tumors than high grades, and SUVmean values were similar in high- and low-grade tumors. This is probably because semiquantitative methods are impaired by tumor tissue heterogeneity, which makes it almost impossible to sample the contribution of each component of tumor to the metabolic activity in the VOI. Nevertheless, a semiquantitative measurement may be just about sufficient for clinical application (Lucignani 2009). Our purpose was to determine the clinical value of SUV values and volume-based metabolic parameters of 18F-FDG Positron emission tomography/Computed tomography (PET/CT), using the semi-automatic techniques, since they are generally accepted quantification methods used in daily practice, easy to perform, and their correlation with more complex measurements and methods is usually good. Consequently, no data was tabulated or qualified regarding the visual characteristics of the lesions (e.g., heterogeneous uptake, necrosis). However, intratumoral metabolic heterogeneity and the presence of necrosis and the volume of necrosis, are adverse prognostic factors for disease recurrence and death in patients with STS (Rakheja et al. 2013, Son et al. 2014).

The SUVmax, MTV and TLG values of the baseline PET/CT have prognostic value for OS, progression-free survival (PFS), and DFS. Patients with high SUVmax, VMT, and TGL values have a lower survival (Li et al. 2016; Chen et al. 2017; Kubo et al. 2016). A meta-analysis concluded that SUVmax, MTV and TLG of baseline PET/CT have prognostic value for OS in STS patients, being useful in identifying high-risk patients (Chen et al. 2017). Schuetze et al. (2005), found significant differences in DFS (p = 0.004) and in OS (p = 0.05), in patients who had a SUVmax value of less than 6 in the baseline study. Better OS and local recurrence have been found in patients with SUVmax less than 10.3 (p = 0.005 and 0.046, respectively) (Sambri et al. 2019 Jun). According to Hong et al. (Hong et al. 2014), SUVmax (p = 0.008) and SUVmean (p = 0.032) are independent predictors of OS in STS patients. In our analysis, the mean OS was 55.2 months, and the mean DFS was 47.9 months. The log rank test outcomes suggest that the SUVmax, SUVpeak, MTV and TLG values of the baseline PET/CT were predictive variables of OS [SUVmax (p = 0.037), SUVpeak (p = 0.05), MTV (p = 0.022), TLG (p = 0.022)]. SUVmax values above 7.10, SUVpeak greater than 6.15, MTV greater than 102.52 cm3, and TLG greater than 335.07, were related to a lower OS. SUVmean value did not correlate with survival but others, and it is probably a consequence of the similarity of the values of the SUVmean in high- and low-grade tumors, due to tumor tissue heterogeneity in high-grade STS (Figs. 7, 8). This aspect of malignancy has long been known and has been described with the histologic features of cellular proliferation, necrosis, noncellular accumulations (matrix material and fibrous tissue), and physiologic characteristics (differences in blood flow, cellular metabolism, oxygenation, and expression of specific receptors). That heterogeneity in tumor metabolism recorded by 18F-FDG uptake is reflective of tumor biologic (Benz et al. 2008; Eary et al. 2008). Another limitation of SUV values normalized by total body weight is that they are affected by the amount of body fat. The SUV of normal tissues and lesions is higher (overestimated) in obese patients than in patients with a normal body mass index (BMI). SUL (SUV normalized by lean body mass [LBM]) is recommended for more accurate results. However, currently, SUL can be used only in obese patients, because the current standard values for differentiating benign from malignant lesions, and reference SUVs (liver, blood pool, and other tissues) have been calculated from patients with a normal BMI or from mixtures of patients with various BMIs. If SUL is going to be used in routine practice, the standard values should be determined in large numbers of people with standard BMI (Sarikaya et al. 2019a).

Fig. 7.

64-year-old male with high-grade spindle cell sarcoma. PET CT showed a mesenteric mass with heterogeneous 18F-FDG uptake

Fig. 8.

43-year-old female with low-grade malignant peripheral nerve sheath Tumor. PET CT showed a solid nodule in the right lower limb with homogeneous uptake of 18F-FDG

A high level of blood glucose competes with 18F-FDG and reduces its uptake in pathologic tissues, and endogenous insulin level also increases, which causes higher 18F-FDG uptake in insulin-sensitive normal tissues (fat and muscle). As a result, hyperglycemia can cause suboptimal differentiation of malignant from benign lesions, and underestimation of tumor grade (Sarikaya et al. 2019b). In our population, median blood glucose (BG) was 128 mg/dl (range 78–186 mg/dl), and patients with high blood glucose levels (over 200 mg/dl) were rescheduled or excluded, depending on the patient’s circumstances. Although guidelines recommend injecting FDG when blood glucose below 200 mg/dl, starting from BG > 110 mg/dl brain FDG uptake gradually and significantly reduces (Sarikaya et al. 2019b; Sprinz et al. 2018). Because there may be a similarity between brain and tumor glucose kinetics, and both brain and tumor show high, GLUT1 and GLUT3 expression (Sarikaya et al. 2019b), maybe tumor uptake is lower in patients with high glucose levels, and when comparing SUVs in high- and low-grade tumors, cases with blood glucose < 150 mg/dl at the time of FDG injection, and chronic hyperglycemia cases, should be avoided for better results for investigation purposes.

Our analysis suggests that SUVmax, SUVmean, and SUVpeak values of baseline 18F-FDG PET/CT are useful to discriminate high-grade from low-grade STS, with a statistically significant relationship between histological grade and SUV values, being the SUVmax value the most significant. Furthermore, we found that patients with high SUVmax, SUVpeak, MTV, and TLG values have significantly lower OS. We can conclude that the 18F-FDG PET/CT is a useful tool in staging patients with STS, and its future incorporation in prognostic nomograms and clinical practice guidelines should be considered.

We consider that the limitations of our study are its retrospective nature, and the heterogeneity of demographics, and histological characteristics. Likewise, it was not possible to carry out an analysis by histological subtypes due to the limitation of the sample because of the low incidence of STS.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.


  1. Bastiaannet E, Groen H, Jager PL, Cobben DC, van der Graaf WT, Vaalburg W, Hoekstra HJ (2004) The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 30(1):83–101

    CAS  Article  Google Scholar 

  2. Beckingsale TB, Shaw C (2017) Epidemiology of bone and soft-tissue sarcomas. Orthop Trauma.

    Article  Google Scholar 

  3. Benz MR, Allen-Auerbach MS, Eilber FC et al (2008) Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med 49(10):1579–1584.

    Article  PubMed  Google Scholar 

  4. Benz MR, Dry SM, Eilber FC, Allen-Auerbach MS, Tap WD, Elashoff D, Czernin J (2010) Correlation between glycolytic phenotype and tumour grade in soft-tissue sarcomas by 18F-FDG PET. J Nucl Med 51(8):1174–1181.

    Article  PubMed  Google Scholar 

  5. Billingsley KG, Burt ME, Jara E et al (1999) Pulmonary metastases from soft-tissue sarcoma. Ann Surg 229:602–612

    CAS  Article  Google Scholar 

  6. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42(2):328–354.

    CAS  Article  Google Scholar 

  7. Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R, Ferlay J (eds) (2017) Cancer incidence in five continents, vol XI (electronic version). International Agency for Research on Cancer, Lyon. Last consulted: January/2020.

  8. Brennan MF, Antonescu CR, Moraco N, Singer S (2014) Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg 260(3):416–422. ((discussion 421–2))

    Article  PubMed  Google Scholar 

  9. Brierley JD, Gospodarowicz MK, Wittekind CH (eds) (2017) TNM classification of malignant tumours, 8th edn. Wiley-Blackwell, Oxford

    Google Scholar 

  10. Carvalho K, Cunha I, Rocha R, Ayala FR, Cajaíba M, Begnami M, Vilela R, Paiva G, Andrade R, Soares F (2011) GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (sao Paulo) 66:965–972.

    Article  Google Scholar 

  11. Chao C, Goldberg M (2000) Surgical treatment of metastatic pulmonary soft-tissue sarcoma. Oncology (williston Park) 14(6):835–841 (discussion 842–4, 847)

    CAS  Google Scholar 

  12. Charest M, Hickeson M, Lisbona R, Novales-Diaz JA, Derbekyan V, Turcotte RE (2009) FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging 36(12):1944–1951.

    Article  PubMed  Google Scholar 

  13. Cheebsumon P, Yaqub M, van Velden FH, Hoekstra OS, Lammertsma AA, Boellaard R (2011) Impact of [18F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology. Eur J Nucl Med Mol Imaging 38(12):2136–2144.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Chen L, Wu X, Ma X, Guo L, Zhu C, Li Q (2017) Prognostic value of 18F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma: a meta-analysis. Medicine (baltimore) 96(6):e5913.

    Article  Google Scholar 

  15. Choi ES, Ha SG, Kim HS et al (2013) Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma. Eur J Nucl Med Mol Imaging 40:1836–1842

    CAS  Article  Google Scholar 

  16. Coindre JM, Terrier P, Guillou L et al (2001) Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91:1914–1926

    CAS  Article  Google Scholar 

  17. Corey RM, Swett K, Ward WG (2014) Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report. Cancer Med 3(5):1404–1415.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Eary JF, O’Sullivan F, O’Sullivan J, Conrad EU (2008) Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor of patient outcome. J Nucl Med 49(12):1973–1979.

    Article  PubMed  Google Scholar 

  19. Esperança-Martins M, Fernandes I, Soares do Brito J, Macedo D, Vasques H, Serafim T, Costa L, Dias S (2021) Sarcoma metabolomics: current horizons and future perspectives. Cells 10(6):1432.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Fletcher CD, Unni KK, Mertens F (eds) (2002) World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon

    Google Scholar 

  21. Fletcher CD, Hogendoorn P, Mertens F, Bridge J (2013) WHO classification of tumours of soft tissue and bone, 4th edn. IARC Press, Lyon

    Google Scholar 

  22. Francis M, Dennis N, Charman J, Lawrence G, Grimer R (2013) Bone and soft tissue sarcomas. UK incidence and survival: 1996 to 2010. Version 2.0. National Cancer Intelligence Network, November 2013. Copyright @ PHE Knowledge & Intelligence Team (West Midlands) 2013. Last consulted: January/2020

  23. Guerra Merino I (2017) Libro Blanco de la Anatomía Patológica en España, 5a edición. Sociedad Española de Anatomía Patológica Gráficas Dosbi, S. L. ISBN 978-84-697-3704-0

  24. Hong SP, Lee SE, Choi YL et al (2014) Prognostic value of 18F-FDG PET/CT in patients with soft tissue sarcoma: comparisons between metabolic parameters. Skeletal Radiol 43:641–648

    Article  Google Scholar 

  25. Ioannidis JP, Lau J (2003) 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med 44(5):717–724

    PubMed  Google Scholar 

  26. Isabel HB, José MV (2020) La Tomografía de emisión de positrones (PET) y la PET-TAC. Dos apuestas seguras para un futuro próximo. Monográfico. Radiología digital. Servicio de Medicina Nuclear. Hospital Universitario “La Fe”, Valencia, España. Last consulted: January/2020.

  27. Key Statistics for Soft Tissue Sarcomas (2019) American Cancer Society. Cancer facts & figures 2019. American Cancer Society, Atlanta. Last consulted: January/2020.

  28. Kinahan PE, Fletcher JW (2010) Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR 31(6):496–505.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Kubo T, Furuta T, Johan MP, Ochi M (2016) Prognostic significance of (18)F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis. Eur J Cancer 58:104–111.

    Article  PubMed  Google Scholar 

  30. Larson SM, Erdi Y, Akhurst T et al (1999) Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 2:159–171

    Article  Google Scholar 

  31. Li YJ, Dai YL, Cheng YS, Zhang WB, Tu CQ (2016) Positron emission tomography (18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma: a meta-analysis. Eur J Surg Oncol 42(8):1103–1114.

    Article  PubMed  Google Scholar 

  32. López-Pousa A, Martín BJ, Martínez Trufero J, Sevilla I, Valverde C, Alvarez R, Carrasco Alvarez JA, Cruz Jurado J, Hindi N, García del Muro (2016) SEOM clinical guideline of management of soft-tissue sarcoma. Clin Transl Oncol 18(12):1213–1220

    Article  Google Scholar 

  33. Lucignani G (2009) SUV and segmentation: pressing challenges in tumour assessment and treatment. Eur J Nucl Med Mol Imaging 36:715–720

    Article  Google Scholar 

  34. Macpherson RE, Pratap S, Tyrrell H, Khonsari M, Wilson S, Gibbons M, Whitwell D, Giele H, Critchley P, Cogswell L, Trent S, Athanasou N, Bradley KM, Hassan AB (2018) Retrospective audit of 957 consecutive 18F-FDG PET–CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma. Clin Sarcoma Res 8(1):9.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Massardo T, Jofré MJ, Sierralta MP, Canessa J, Castro G, Berrocal I, Gallegos I (2012) Utilidad del estudio PET con FDG en la evaluación de sarcomas de diverso origen y de tumores no sarcoma-no epiteliales. Rev Med Chil 140(9):1116–1125.

    Article  PubMed  Google Scholar 

  36. Meyer H-J, Wienke A, Surov A (2019) Associations between GLUT expression and SUV values derived from FDG-PET in different tumors—a systematic review and meta analysis. PLoS ONE 14:e0217781.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. Miele E, Spinelli G, Tomao F, Zullo A, de Marinis F, Pasciuti G, Rossi L, Zoratto F, Tomao S (2008) Positron Emission Tomography (PET) radiotracers in oncology—utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC). J Exp Clin Cancer Res CR 27:52.

    CAS  Article  PubMed  Google Scholar 

  38. Mucientes J, Calles L, Rodríguez B, Mitjavila M (2018) Parameters of metabolic quantification in clinical practice. Is it now time to include them in reports? Rev Esp Med Nucl Imagen Mol 37(4):264–270.

    CAS  Article  PubMed  Google Scholar 

  39. National Cancer Society (NCS) (2020) How are soft tissue sarcomas staged? Last consulted: January/2020

  40. Nose H, Otsuka H, Otomi Y, Terazawa K, Takao S, Iwamoto S, Harada M (2013) Correlations between F-18 FDG PET/CT and pathological findings in soft tissue lesions. J Med Investig 60(3–4):184–190.

    Article  Google Scholar 

  41. Proyecto de Acciones para que el Gobierno actúe sobre el Sarcoma (plan 2019–2020). Grupo GEIS. Last consulted: January/2020.

  42. Rakheja R, Probst S (2013) Is it time to incorporate fludeoxyglucose PET/CT markers into sarcoma prediction models? Imaging Med 5:295–297.

    CAS  Article  Google Scholar 

  43. Rakheja R, Makis W, Tulbah R, Skamene S, Holcroft C, Nahal A, Turcotte R, Hickeson M (2013) Necrosis on FDG PET/CT correlates with prognosis and mortality in sarcomas. AJR Am J Roentgenol 201:170–177.

    Article  PubMed  Google Scholar 

  44. Rodríguez-Alfonso B, Mucientes Rasilla J, Mitjavila Casanovas M, Cardona Arboniés J, Cubedo R (2014) 18F-FDG-PET-CT in soft tissue sarcomas: when to image? Rev Esp Med Nucl Imagen Mol 33(1):43–49.

    Article  PubMed  Google Scholar 

  45. Sambri A, Bianchi G, Longhi A, Righi A, Donati DM, Nanni C, Fanti S, Errani C (2019) The role of 18F-FDG PET/CT in soft tissue sarcoma. Nucl Med Commun 40(6):626–631.

    CAS  Article  PubMed  Google Scholar 

  46. Sarcomas en la Infancia. Gobierno de España. Ministerio de Sanidad, Consumo y Bienestar Social. Last consulted: January/2020.

  47. Sarikaya I, Albatineh A, Sarikaya A (2019a) Re-visiting SUV-weight and SUV-lean body mass in FDG PET studies. J Nucl Med Technol.

    Article  PubMed  Google Scholar 

  48. Sarikaya I, Sarikaya A, Sharma P (2019b) Assessing the Effect of various blood glucose levels on 18F-FDG activity in the brain, liver, and blood pool. J Nucl Med Technol 47(4):313–318

    Article  Google Scholar 

  49. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU 3rd, Eary JF (2005) Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 103(2):339–348

    Article  Google Scholar 

  50. Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F et al (2000) Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 231:380–386

    CAS  Article  Google Scholar 

  51. Son SH, Kim DH, Hong CM et al (2014) Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast. BMC Cancer 14:585.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Sprinz C, Zanon M, Altmayer S et al (2018) Effects of blood glucose level on 18F fluorodeoxyglucose (18F-FDG) uptake for PET/CT in normal organs: an analysison 5623 patients. Sci Rep 8:2126

    Article  Google Scholar 

  53. Stiller CA, Trama A, Serraino D, Rossi S, Navarro C, Chirlaque MD, Casali PG (2013) Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer 49(3):684–695. ISSN 0959-8049

  54. Thie JA (2004) Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45(9):1431–1434

    PubMed  Google Scholar 

  55. Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, Goussot JF, David M, Bonichon F, Lagarde C (1984) Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 33(1):37–42

    CAS  Article  Google Scholar 

  56. Tsukada H, Muramatsu T, Miyazawa M, Iida T, Ikeda M, Shida M, Hirasawa T, Kajiwara H, Murakami M, Yasuda M, Mikami M (2012) Long term prognostic implications of expression of glucose Transporter-1 and Hexokinase II in patients with Stage I Uterine Leiomyosarcoma. Acta Histochemica et Cytochemica 45(2):147–154. Released April 26, 2012, [Advance publication] Released April 21, 2012, Online ISSN 1347-5800, Print ISSN 0044-5991

  57. Vanderhoek M, Perlman SB, Jeraj R (2013) Impact of different standardized uptake value measures on PET-based quantification of treatment response. J Nucl Med 54(8):1188–1194.

    CAS  Article  PubMed  Google Scholar 

  58. Vilanova JC (2017) WHO classification of soft tissue tumours. In: Imaging of soft tissue tumours, pp 187–196.

  59. Villalobos León ML (2013) Sarcoma de partes blandas. Medicine Programa De Formación Médica Continuada Acreditado 11(27):1659–1668.

    Article  Google Scholar 

  60. Yang H, Zhong J-T, Zhou S-H, Han H-M (2019) Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer. Oncotarget.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


Not applicable.


We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work.

Author information




All authors made substantial contributions to the conception, design, data acquisition, and statistical analysis of this publication, providing the necessary information, references, and corrections. The first draft of the manuscript was written by RMRH, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Rafael Hernando Reyes Marlés.

Ethics declarations

Ethics approval and consent to participate

Our study is a retrospective. For this type of study, formal consent is not required.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Reyes Marlés, R.H., Navarro Fernández, J.L., Puertas García-Sandoval, J.P. et al. Clinical value of baseline 18F-FDG PET/CT in soft tissue sarcomas. European J Hybrid Imaging 5, 16 (2021).

Download citation


  • FDG
  • PET/CT
  • SUV
  • MTV
  • TLG
  • Soft tissue sarcomas